- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04207463
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
A Phase II, Open, Single-arm, Multi-cohort, Multicenter Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Not yet recruiting
- Beijing Hospital
-
Contact:
- Yunbo Zhao, Doctor
- Phone Number: 010-85136715
-
Principal Investigator:
- Yunbo Zhao, Doctor
-
Beijing, Beijing, China, 100730
- Not yet recruiting
- Peking Union Medical College Hospital
-
Contact:
- Jianfeng Zhou, Doctor
- Phone Number: 010-69158750
-
Principal Investigator:
- Jianfeng Zhou, Doctor
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
-
Principal Investigator:
- Aiping Zhou, Doctor
-
Contact:
- Aiping Zhou, Doctor
- Phone Number: 021-38804518
- Email: zhouap1825@126.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Jiangsu Cancer Hospital
-
Contact:
- Jifeng Feng, Doctor
- Phone Number: 025-83283415
-
Principal Investigator:
- Jifeng Feng, Doctor
-
-
Jilin
-
Harbin, Jilin, China, 150081
- Not yet recruiting
- Harbin Medical University Cancer Hospital
-
Contact:
- Yanqiao Zhang, Doctor
- Phone Number: 0451-86298278
-
Principal Investigator:
- Yanqiao Zhang, Doctor
-
-
Shandong
-
Jinan, Shandong, China, 250013
- Recruiting
- Jinan Central Hospital
-
Principal Investigator:
- Yuping Sun, Doctor
-
Contact:
- Yuping Sun, Doctor
- Phone Number: 0531-68623306
-
-
Shanxi
-
Xi'an, Shanxi, China, 710061
- Not yet recruiting
- Shanxi Provincial Cancer Hospital
-
Contact:
- Zijun Liao, Doctor
- Phone Number: 029-85276142
-
Principal Investigator:
- Zijun Liao, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Cohort 1:Histopathologically confirmed metastatic or inoperable cholangiocarcinoma failed with first-line or above chemotherapy.
Cohort 2: Histopathologically confirmed recurrent or metastatic colorectal cancer that is not suitable for surgery with MSI-H or dMMR.
Cohort 3: Histopathologically confirmed metastatic or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Cohort 4:Histopathologically confirmed local progression or metastatic urothelial carcinoma that is not suitable for surgery.
Cohort 5:Low- and medium-grade (G1 or G2) late gastrointestinal pancreatic neuroendocrine tumor (NET) subjects diagnosed by pathology." 2.18 years and older; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Life expectancy ≥ 3 months.
3.At least one measurable lesion. 4.The main organs function are normally. 5. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
6. Understood and signed an informed consent form.
Exclusion Criteria:
1.Has used anti-angiogenic drugs such as bevacizumab, erlotinib, apatinib, sorafenib, sunitinib, and endothelium or against PD-1, PD-L1 and other related immunotherapeutic drugs.
2. HER2 positive in cohort 3. 3. Has received chemotherapy, radiotherapy or other treatments within 4 weeks prior to the first dose.
4.Has brain metastases with symptoms or symptoms control for less than 2 months.
5.Has diagnosed and/or treated additional malignancy within 5 years prior to the first dose.
6.Has multiple factors affecting oral medication. 7.Has uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
8.Has unrelieved spinal cord compression. 9.Imaging shows that tumors invade large blood vessels. 10.Has hemoptysis within 1 month prior to the first dose and maximum daily hemoptysis ≥2.5 mL.
11.Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
12.Has received surgery, or unhealed wounds within 4 weeks before the first dose.
13. Has artery/venous thrombosis prior to the first dose within 6 months. 14. Has drug abuse history that unable to abstain from or mental disorders 15. Has any serious and / or uncontrolled disease. 16. Has received vaccination or attenuated vaccine within 4 weeks prior to the first dose.
17.Hypersensitivity to recombinant humanized anti-PD-1 monoclonal or its components.
18. Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first dose.
19.Diagnosed as immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy (dose >10 mg/day of prednisone or other therapeutic hormones) and continued to be used for 2 weeks prior to the first dose 20. Has participated in other anticancer drug clinical trials within 4 weeks. 21. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anlotinib and AK105 injection
AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
|
a multi-target receptor tyrosine kinase inhibitor
AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR).
|
up to 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: up to 96 weeks
|
DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.
|
up to 96 weeks
|
Disease control rate(DCR)
Time Frame: up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
up to 96 weeks
|
Progression-free survival (PFS)
Time Frame: up to 96 weeks
|
PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.
|
up to 96 weeks
|
Overall survival (OS)
Time Frame: up to 120 weeks
|
OS defined as the time from the first dose to death from any cause.
Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 120 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Gastrointestinal Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Urologic Neoplasms
- Neuroendocrine Tumors
Other Study ID Numbers
- ALTN-AK105-II-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
-
Hellenic Cooperative Oncology GroupNovartisTerminatedGastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine TumorsGreece
-
Wuerzburg University HospitalRecruitingGastrointestinal CancerGermany
-
University of Wisconsin, MadisonCompletedNeuroendocrine TumorUnited States
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaRecruitingMelanoma | Breast Cancer | Gastrointestinal Neuroendocrine TumorCanada
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
SCRI Development Innovations, LLCIpsenTerminatedGastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid TumorsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
Oslo University HospitalUniversity Hospital of North Norway; Haukeland University Hospital; St. Olavs...RecruitingPancreatic Neuroendocrine Tumors, WHO Grade I-IINorway
Clinical Trials on Anlotinib
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Peking Union Medical College HospitalRecruitingParaganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, MalignantChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
Hunan Cancer HospitalFuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...RecruitingSmall Cell Lung CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina